Clinical trial · Observational
Sienna+MR Long-term Uptake
Feasibility of Breast MRI After Sentinel Procedure for Breast Cancer With Superparamagnetic Tracers
NCT03243435CI-TRIAL-00028996completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In a previous study in 2012/2013 patients were injected a superparamagnetic iron oxide for sentinel lymph node detection. In this follow up study we want to investigate how much of this tracer is still detectable.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Female | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Native 1,5 Tesla breast MRI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Native 1,5 Tesla breast MRI group
- description
- From all patients a 1,5 Tesla MRI of the breast will be obtained
- interventionNames
- Procedure: Native 1,5 Tesla breast MRI
Primary outcomes (1)
- measure
- I) Analysis if the supraparamegnetic Tracer is still detectable
- timeFrame
- 04/2017
- description
- Analysis by two expert radiologists
Secondary outcomes (1)
- measure
- Analysis to which degree of impairment of Imaging is detected
- timeFrame
- 04/2017
- description
- Description as "no impairment", impairment, but Interpretation of Images possible", "impairment, Image Interpretation impossible"
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
inclusion: * participation in previous study * informed consent * no contraindications for MRI scan exclusion: * contraindications for MRI scan
References
Publications (0)
Data not yet available
No reference posted for this study.